Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 17

679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor

Date

21 Oct 2023

Session

Poster session 17

Topics

Clinical Research;  Therapy;  Cancer in Special Situations/ Populations

Tumour Site

Presenters

Irene Moreno

Citation

Annals of Oncology (2023) 34 (suppl_2): S458-S497. 10.1016/S0923-7534(23)01936-1

Authors

I. Moreno1, T. Hernandez2, E. Calvo1, S. Fudio3, C. Kahatt3, S. Martinez3, J. Iglesias3, R.O. Calafati4, L. Pérez Ramos3, L. Montilla3, A. Zeaiter3, R. Lubomirov3

Author affiliations

  • 1 Oncology, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, 28050 - Madrid/ES
  • 2 Oncology, START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain Current address: START Barcelona-HM CIOCC Early Phase Program, Hospital HM Nou Delfos, 08023 - Barcelona/ES
  • 3 Clinical Development, PharmaMar, 28770 - Colmenar Viejo, Madrid/ES
  • 4 Clinical Development, PharmaMar, Colmenar Viejo, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 679P

Background

LRB is a highly selective inhibitor of oncogenic transcription primarily metabolized by CYP3A4. This study investigated whether the PK and safety profile of LRB is affected by co-administration with ITZ, a strong CYP3A4 inhibitor, in adult patients with advanced solid tumors.

Methods

This was a 2-part crossover, open-label, phase Ib drug-drug interaction study (NCT05063318). In Part A, 3 patients were assigned to sequence 1 (TR) receiving a cycle (C) 1 of LRB (0.8 mg/m2, 1 hour [h], iv) co-administered with ITZ (200 mg/day oral; 12-days), followed by a C2 of LRB alone (3.2 mg/m2, 1 h, iv). In Part B, 11 patients were randomized (1:1) to receive either sequence 1 (TR) or 2 (RT). Plasma samples for LRB and ITZ PK were collected.

Results

11 patients were evaluable for the primary objective of the study: 3 patients in Part A and 8 patients in Part B (4 in each of sequences 1 and 2). The systemic exposure of LRB was increased [15% for Cmax, 2.4-fold for AUC0-t and 2.7-fold for AUC0-∞] with ITZ co-administration. This correlated with reduced clearance (CL) by 63% and prolonged elimination half-life (t1/2) by 2.2-fold. Co-administration with ITZ produced statistically significant modifications in the unbound plasma LRB PK parameters of similar extent than in total plasma with a 2.2-fold and 2.4-fold increase in AUC0-t and AUC0-∞, respectively compared to LRB alone. Unbound LRB CL decreased by 58% and t1/2 was 2-fold longer. Consistent with previous studies, the most common treatment-related adverse events of LRB alone at dose of 3.2 mg/m2 were neutropenia, nausea, vomiting and fatigue. Safety profile of LRB at a dose of 0.9 mg/m2 when co-administered with ITZ was no worse than that of LRB administered alone at 3.2 mg/m2.

Conclusions

In comparison with LRB alone, the co-administration with multiple doses of ITZ, significantly altered LRB systemic exposure reducing total plasma (by 63%) and unbound (by 58%) LRB CL. The magnitude of these changes showed a clinically relevant effect of ITZ co-administration on LRB PKs. To avoid LRB overexposure and a worst safety profile when co-administered with strong CYP3A4 inhibitors a LRB dose reduction proportional to CL reduction should be applied.

Clinical trial identification

NCT05063318.

Editorial acknowledgement

Legal entity responsible for the study

PharmaMar.

Funding

PharmaMar.

Disclosure

E. Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, TargImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diaccurate; Financial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech; Financial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospitales Group; Financial Interests, Personal, Full or part-time Employment, Medical Oncologist. Clinical Investigator. Director, Clinical Research: START Madrid-CIOCC (Centro Integral Oncológico Clara Campal); Financial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar; Financial Interests, Personal, Ownership Interest: START, Oncoart Associated; Financial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus; Financial Interests, Personal, Steering Committee Member: Novartis; Non-Financial Interests, Other, Non-for-profit Foundation. President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation; Non-Financial Interests, Advisory Role: PsiOxus; Non-Financial Interests, Other, Chair of the Independent Data Monitoring Committee: EORTC IDMC; Non-Financial Interests, Member of Board of Directors, Non-for-profit Foundation, trustee member: Non-for-profit Foundation PharmaMar; Non-Financial Interests, Advisory Role, Non-for-profit foundation: CRIS Cancer Foundation, non-for-profit ; Non-Financial Interests, Member: ASCO, ESMO, SEOM, EORTC. S. Fudio: Financial Interests, Personal, Stocks or ownership: PharmaMar. C. Kahatt, J. Iglesias, R.O. Calafati, L. Pérez Ramos, L. Montilla, A. Zeaiter, R. Lubomirov: Financial Interests, Stocks or ownership: PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.